kabutan

Tsubota Laboratory Incorporated(4890) Summary

4890
TSE Growth
Tsubota Laboratory Incorporated
397
JPY
-16
(-3.87%)
Mar 16, 10:35 am JST
2.49
USD
Mar 15, 9:35 pm EDT
Result
PTS
outside of trading hours
397
Mar 16, 10:35 am JST
Summary Chart Historical News Financial Result
PER
PBR
9.27
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 16, 2026
Opening Mar 16, 9:00 am
421 JPY 2.63 USD
Previous Close Mar 13
413 JPY 2.59 USD
High Mar 16, 9:01 am
446 JPY 2.79 USD
Low Mar 16, 10:33 am
391 JPY 2.45 USD
Volume
1,768,900
Trading Value
0.75B JPY 4.70M USD
VWAP
423.57 JPY 2.66 USD
Minimum Trading Value
39,700 JPY 249 USD
Market Cap
0.01T JPY 0.06B USD
Number of Trades
3,467
Liquidity & Number of Trades
As of Mar 16, 2026
Liquidity
Mid
1-Year Average
269
1-Year High Mar 13, 2026
17,552
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 567,500
Feb 27, 2026 0 567,800
Feb 20, 2026 0 587,500
Feb 13, 2026 0 650,900
Feb 6, 2026 0 615,600
Company Profile
Tsubota Laboratory Incorporated is a biotech venture originating from Keio University. The company focuses on research and development of pharmaceuticals for myopia, dry eye, presbyopia, and brain activation.
Sector
Pharmaceuticals
Tsubota Laboratory Incorporated, a biotech venture born out of Keio University School of Medicine, aims to create groundbreaking innovations in the treatment of myopia, dry eye, presbyopia, and brain-related disorders. The company conducts advanced research in collaboration with affiliated universities and pursues joint development with partner companies to evaluate research outcomes. Its business model is based on generating revenue through joint research and development agreements, licensing agreements, upfront payments, milestone payments, and post-commercialization royalties, which are then reinvested into new research in a cyclical manner. A distinctive feature of the company is its research and development utilizing the high-level expertise of external contracted researchers. Tsubota Laboratory Incorporated adopts a dual strategy, simultaneously developing and marketing pharmaceuticals and medical devices alongside commodity products.